Low Dose of KBP-COVID-19 for Coronavirus

"The first low-dose study of KBP-COVID-19 was completed in 2020 at LMC Manna Research. A total of 18,244 studies have been completed thus far. There is currently one live study, with several trials taking place in Burlington, Burlington/Ontario."

"As of right now, there is a single study concerning Low Dose of KBP-COVID-19 that is still active. It began in 2020 and is being conducted across 8 cities in 2 different countries. The study is sponsored by Kentucky BioProcessing, Inc. and thus far 101 people have participated. It completed its Phase 1 & 2 approvals in 2020, and since then 18244 other trials have been completed."

"This clinical trial is recruiting 101 patients that have covid-19 and are between 18 and 85 years old. Candidates are required to meet the following criteria: Must be able to attend all visits, including unscheduled visits if respiratory symptoms develop during the study, for the duration of the study and comply with all study procedures, including daily completion of the Diary Card for 7 days after each injection., Subject read, understood, and signed the informed consent form (ICF)., Healthy adult males and females 18-49 years of age (Part A) or 50-85 years of age (Part B), inclusive, at"

"The age bracket for individuals that this study is looking to recruit are those that are over 18 and under 85."

"The primary outcome of this trial is solicited systemic events, which will be measured over the course of 7 days after vaccination. Secondary objectives include serious adverse events, medically attended adverse events, and new onset chronic disease (defined as safety endpoints), vaccine ELISA and neutralizing antibody titers for each treatment group (defined as immunogenicity), and unsolicited adverse events and medically attended adverse events (defined as safety endpoints)."